The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Projected Cost-effectiveness of Pneumococcal Conjugate Vaccination of Healthy Infants and Young Children
Abstract
CONTEXT: Pneumococcal conjugate vaccine for infants has recently been found effective against meningitis, bacteremia, pneumonia, and otitis media. OBJECTIVE: To evaluate the projected health and economic impact of pneumococcal conjugate vaccination of healthy US infants and young children. DESIGN: Cost-effectiveness analysis based on data from the Northern California Kaiser Permanente randomized trial and other published and unpublished sources. SETTING AND PATIENTS: A hypothetical US birth cohort of 3.8 million infants. INTERVENTIONS: Hypothetical comparisons of routine vaccination of healthy infants, requiring 4 doses of pneumococcal conjugate vaccine (at 2, 4, 6, and 12-15 months), and catch-up vaccination of children aged 2 to 4.9 years requiring 1 dose, with children receiving no intervention. MAIN OUTCOME MEASURES: Cost per life-year saved and cost per episode of meningitis, bacteremia, pneumonia, and otitis media prevented. RESULTS: Vaccination of healthy infants would prevent more than 12000 cases of meningitis and bacteremia, 53000 cases of pneumonia, 1 million episodes of otitis media, and 116 deaths due to pneumococcal infection. Before accounting for vaccine costs, the vaccination program would save $342 million in medical and $415 million in work-loss and other costs from averted pneumococcal disease. Vaccination of healthy infants would result in net savings for society if the vaccine cost less than $46 per dose, and net savings for the health care payer if the vaccine cost less than $18 per dose. At the manufacturer's list price of $58 per dose, infant vaccination would cost society $80000 per life-year saved or $160 per otitis media episode prevented (other estimated costs would be $3200 per pneumonia case prevented, $15000 for bacteremia, and $280000 for meningitis). The cost-effectiveness of an additional program to administer 1 dose of vaccine to children aged 2 to 4.9 years would vary depending on the children's ages, relative risks of pneumococcal disease, and vaccine cost. CONCLUSIONS: Pneumococcal conjugate vaccination of healthy US infants has the potential to be cost-effective. To achieve cost savings, its cost would need to be lower than the manufacturer's list price. In addition to tangible costs, the vaccine should be appraised based on the less tangible value of preventing mortality and morbidity from pneumococcal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
BLACK, S., SHINEFIELD, H., FIREMAN, B., LEWIS, E., RAY, P., HANSEN, J. R., ELVIN, L., ENSOR, K. M., HACKELL, J., SIBER, G., et al. (2000) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200003000-00003 · Cited by 2,293
Teele, D. W., Klein, J. O., Rosner, B., & Greater Boston Otitis Media Study Group (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/160.1.83 · Cited by 1,492
Bacterial Meningitis in the United States in 1995
Schuchat, A., Robinson, K., Wenger, J. D., Harrison, L. H., Farley, M., Reingold, A. L., Lefkowitz, L., & Perkins, B. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710023371404 · Cited by 1,251
(1997) · PubMed · Cited by 784
Emergence of Drug-Resistant Pneumococcal Infections in the United States
Breiman, R. F. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510470035031 · Cited by 562
Immunogenicity and Impact on Nasopharyngeal Carriage of a Nonavalent Pneumococcal Conjugate Vaccine
Mbelle, N., Huebner, R. E., Wasas, A. D., Kimura, A., Chang, I., & Klugman, K. P. (1999) · The Journal of Infectious Diseases · doi:10.1086/315009 · Cited by 515
McIntyre, P. B. (1997) · JAMA · doi:10.1001/jama.278.11.925 · Cited by 416
Otitis Media in Infants and Children
Klein, J. O. (2000) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200009080-00005 · Cited by 379
Cost-effectiveness Analysis of a Rotavirus Immunization Program for the United States
Tucker, A. W. (1998) · JAMA · doi:10.1001/jama.279.17.1371 · Cited by 355
Cited by
Bradley, J. S., Byington, C. L., Shah, S. S., Alverson, B., Carter, E. R., Harrison, C., Kaplan, S. L., Mace, S. E., McCracken, G. H., Moore, M. R., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir531 · Cited by 1,919
Impact of the pneumococcal conjugate vaccine on otitis media
FIREMAN, B., BLACK, S. B., SHINEFIELD, H. R., LEE, J., LEWIS, E., & RAY, P. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200301000-00006 · Cited by 477
KILPI, T., HERVA, E., KAIJALAINEN, T., SYRJÄNEN, R., & TAKALA, A. K. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200107000-00004 · Cited by 299
Zhou, F., Shefer, A., Kong, Y., & Nuorti, J. P. (2008) · Pediatrics · doi:10.1542/peds.2007-0619 · Cited by 273
Population-wide benefits of routine vaccination of children against influenza
Weycker, D., Edelsberg, J., Elizabeth Halloran, M., Longini, I. M., Nizam, A., Ciuryla, V., & Oster, G. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.08.044 · Cited by 266
Metadata
- Authors
- Lieu, T. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2000-03-15
- Volume
- 283
- Issue
- 11
- Pages
- 1460
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2100212030
- Cited by
- 279
- References
- 29
- FWCI
- 27.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Projected Cost-effectiveness of Pneumococcal Conjugate Vaccination of Healthy Infants and Young Children. https://app.cochat.ai/papers/10.1001/jama.283.11.1460
- The paper
- Lieu, T. A. (2000). Projected Cost-effectiveness of Pneumococcal Conjugate Vaccination of Healthy Infants and Young Children. JAMA. https://doi.org/10.1001/jama.283.11.1460
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.